SEC Tracker
Get the app

BioNexus Gene Lab BGLC

BioNexus Gene Lab FY 2023: revenue $9.8M, down 11%; diluted EPS −$0.17

Form
10-K/A
Filed
Period
Importance
Routine
Document
10-K/A

Key figures from this report

These are the numbers BioNexus Gene Lab reported for the year ended Dec 31, 2023, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$9.8M−11% from $10.9M in FY 202210-K income statement, on EDGAR
  2. Net income−$2.6MAgainst −$356K in FY 202210-K income statement, on EDGAR
  3. Diluted EPS−$0.17No year-earlier figure tagged10-K income statement, on EDGAR
  4. Cash and cash equivalents$5.9M+180% from $2.1M in FY 202210-K balance sheet, on EDGAR
  5. Cash from operations−$1.3M−339% from $544K in FY 202210-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when BioNexus Gene Lab files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 8071 and related industry codes: the same peer list as the financial tables.

  1. Aclarion ACON public float $4M, Jun 30, 2025
  2. Advanced Biomed ADVB public float $3M, Dec 31, 2025
  3. Ludwig Enterprises LUDG public float $10M, Jun 30, 2025
  4. CapForce CFOR public float $12M, Jun 30, 2025
  5. American Shared Hospital Services AMS public float $12M, Jun 30, 2025